News from fate therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 04, 2012, 08:00 ET

Fate Therapeutics Strengthens Leadership Position In The Development Of Wnt-based Protein Therapeutics

 Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced...

Nov 27, 2012, 08:00 ET

Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies

Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the...

Oct 15, 2012, 07:30 ET

Fate Therapeutics Appoints Christian Weyer As President And Chief Executive Officer

Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to...

Jun 11, 2012, 08:00 ET

Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications

 Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the...

Dec 14, 2011, 07:30 ET

Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO

 Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive...

Dec 13, 2011, 07:30 ET

Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference

 Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as...

Dec 09, 2011, 07:30 ET

Fate Therapeutics Secures Foundational Patent for iPS Cell Reprogramming

Fate Therapeutics, Inc. announced today that the United States Patent and Trademark Office has granted a patent covering compositions that are...

Nov 16, 2011, 08:00 ET

Fate Therapeutics Strengthens Its iPSC Platform

Fate Therapeutics, Inc. announced today that the United States Patent and Trademark Office has granted a patent covering the novel stem cell...

Feb 21, 2011, 17:42 ET

Fate Therapeutics Announces Encouraging Clinical Results and Change in Management

In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate...

Feb 21, 2011, 17:40 ET

Fate Therapeutics Announces Emerging Data From Proof-of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in...

Oct 14, 2010, 08:00 ET

Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology

Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical...

Jun 28, 2010, 08:00 ET

Fate Therapeutics Receives Red Herring's North America 100 Award for Advancing Stem Cell Technology and New Medicines

Fate Therapeutics, Inc. announced today that the Company received Red Herring's North America 100 award, a prestigious list honoring the year's...

May 11, 2010, 08:00 ET

Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline

Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company's Scientific Advisory Board (SAB).  The new...

May 10, 2010, 08:00 ET

Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery

Fate Therapeutics, Inc. announces the appointment of Tom Novak, Ph.D., as vice president of research and drug discovery.  Dr. Novak brings to...

Apr 08, 2010, 08:00 ET

Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in...

Feb 26, 2010, 08:00 ET

Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of...

Feb 04, 2010, 08:00 ET

Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number...

Dec 21, 2009, 08:00 ET

Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs

Fate Therapeutics, Inc. announced today that the Company's iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the...

Nov 16, 2009, 08:00 ET

Fate Therapeutics Closes $30 Million Series B Financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP...

Oct 18, 2009, 13:00 ET

Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming

Fate Therapeutics, Inc. announced today the generation of human induced pluripotent stem cells (iPSCs) using a combination of small...